

Signal Law Group Issues Vigilant Risk Score™ Bulletin on Silexion Therapeutics Corp. (NYSE: SLXN) and Flags Risk Indicators

NEW YORK, NY, June 15, 2026 – Signal Law Group has issued a Vigilant Risk Score™ bulletin on Silexion Therapeutics Corp. (SLXN), highlighting elevated risk indicators tied to repeated reverse stock splits and significant increases in authorized share capital. These events, analyzed within the Vigilant Risk Score™ framework, point to potential dilution concerns and a reliance on ongoing equity issuance that may be material to investors.

Investigation Overview

Signal Law Group initiated this bulletin after Silexion Therapeutics Corp. executed multiple reverse stock splits within a two-year period, including a recent 1-for-10 split in May 2026, while also substantially increasing its authorized share capital. These actions were undertaken to help maintain Nasdaq listing standards and support financing efforts but may have implications for existing shareholders. The review focuses on how these capital structure changes intersect with securities disclosure obligations and investor expectations.

The current Vigilant Risk Score™ for Silexion Therapeutics Corp. is 65 | Yellow, with an Event Momentum Signal (EMS) characterized as Building and a Legal Risk Indicator (LRI) assessed as Forming.

Company Overview

Silexion Therapeutics Corp. is a publicly traded biotechnology company operating under the ticker symbol SLXN. The company has recently engaged in multiple reverse stock splits, including a 1-for-10 split in May 2026, as part of its efforts to manage its share price and maintain exchange compliance.

In parallel, Silexion Therapeutics Corp. has implemented a substantial increase in its authorized share capital to facilitate ongoing financing activities. These strategic capital measures have drawn attention from investors concerned about potential shareholder dilution and the company's reliance on repeated equity issuance to fund operations.

Scope of Review

Signal Law Group's current review focuses on how Silexion Therapeutics Corp. has disclosed and structured its recent reverse stock splits and significant increases in authorized share capital in light of securities disclosure obligations. The bulletin examines whether investors received clear, timely, and complete information about the potential dilutive impact of these actions and the company's

ongoing reliance on equity issuance for financing. Signal is also reviewing how these capital decisions relate to efforts to maintain Nasdaq listing compliance and the broader pattern of shareholder-impacting events.

"Signal's bulletin is focused on whether Silexion's repeated reverse stock splits and large increases in authorized shares were matched by clear, decision-useful disclosures for investors. Our structured review looks at how these capital structure changes interact with listing compliance pressures and ongoing equity financing, and whether the overall pattern presents elevated dilution and securities disclosure risk signals within our Vigilant Risk Score framework." said Lou Schwartz, Chief Forensic Officer of Signal Law Group.

No Legal Action Statement

No legal action has been initiated by Signal Law Group at this time. This bulletin reflects an ongoing structured forensic review and is not a determination of wrongdoing. Signal will evaluate next steps based on data development, regulatory response, and applicable law.

Why this matters: Repeated reverse stock splits and substantial increases in authorized share capital can significantly affect existing shareholders through dilution and changes to trading dynamics. When these actions are closely tied to maintaining exchange compliance and ongoing equity-based financing, investors may face heightened exposure if disclosures are incomplete or difficult to interpret. The securities disclosure issues flagged here focus on whether market participants had a clear view of Silexion's capital strategy and dilution risks. These factors are increasingly important in volatile small-cap and biotech names where financing cycles can drive shareholder outcomes.

Public Research Profile

Signal Law Group has launched a dedicated public research profile for this matter. Individuals may follow updates and submit information confidentially. Data submitted through the research portal may contribute to Signal's ongoing forensic analysis and clustering review.

[View Investigation](#)

[Submit Information](#)

Video Overview

A short video outlining the scope of the bulletin and the Vigilant Risk Score™ framework is available here:

FAQ

Q: What is the Vigilant Risk Score™ (VRS™)?

A: The Vigilant Risk Score™ is Signal Law Group's forensic analytics model designed to evaluate risk indicators associated with potential consumer liability exposure, using structured signals such as complaint clustering trends, disclosure consistency, and subscription representation patterns.

Q: What does "elevated indicators" mean in this bulletin?

A: It means the model's risk thresholds were met based on the inputs analyzed, suggesting patterns that merit further review. It is not a legal finding and not a determination of wrongdoing.

Q: Is Signal Law Group suing Silexion Therapeutics Corp.?

A: No. Signal Law Group has not initiated legal action at this time. The bulletin reflects an ongoing forensic review.

Q: What is the scope of Signal's forensic review here?

A: The scope centers on securities disclosure issues related to Silexion's multiple reverse stock splits and its substantial increase in authorized share capital. Signal is reviewing whether communications around these capital structure changes adequately addressed dilution risks and the company's reliance on repeated equity issuance to maintain compliance and secure financing.

Q: How can someone share information with Signal Law Group?

A: Individuals can submit information confidentially through the public research profile.

Q: How will submitted information be used?

A: Submissions may be used to inform Signal's ongoing analysis, including evaluating whether reported issues cluster in ways that suggest repeatable patterns. Signal may also review publicly available materials related to the submission where appropriate.

Q: Will Signal Law Group provide updates?

A: Yes. Signal intends to publish periodic bulletins and updates as the analysis develops and as relevant data signals evolve.

About Signal Law Group

Signal Law Group is a New York-based research and investigations firm focused on identifying recurring corporate conduct patterns across consumer, financial, and technology sectors. The firm

applies structured forensic analytics, including the Vigilant Risk Score™ methodology, to detect measurable risk indicators and emerging patterns that may warrant further review. Signal Law Group also makes certain analytical dashboards and monitoring outputs available to select institutional stakeholders under structured arrangements.

Media Contact

Signal Law Group

New York, New York

info@signallawgroup.com

www.signallawgroup.com

This bulletin is based on information believed to be reliable as of the date of publication. Signal Law Group does not undertake any obligation to update this bulletin. All statements other than statements of historical fact may be considered forward-looking and are subject to uncertainties and risks that could cause actual outcomes to differ. This document is provided for informational purposes only and does not constitute legal advice, investment advice, or a recommendation regarding any security, strategy, or company. Readers should conduct their own analysis and consult with qualified professionals before making any investment or legal decisions. Signal Law Group makes no representation or warranty, express or implied, as to the accuracy, completeness, or fitness of the information for any purpose.